- Open Access
Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti
© The Author(s) 2017
Received: 12 May 2017
Accepted: 8 August 2017
Published: 17 August 2017
Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class.
Production of elansolid A2 by C. sancti was enabled using a synthetic medium with sucrose as carbon source to a final concentration of 18.9 mg L−1. A fed-batch fermentation was ensued that resulted in an elansolid A2 concentration of 55.3 mg L−1. When using glucose as carbon source in a fed-batch fermentation only 34.4 mg L−1 elansolid A2 but 223.1 mg L−1 elansolid C1 were produced. This finding was not unexpected since elansolids A1/A2 and A3 have been reported to easily react with nucleophiles like anthranilic acid, a precursor of tryptophan biosynthesis. Due to the fact that nucleophiles can be incorporated in vivo, a fed-batch cultivation under identical conditions, with addition of anthranilic acid was carried out and lead to almost exclusive formation of elansolid C1 (257.5 mg L−1).
Reproducible elansolid A2 and C1 production is feasible in different synthetic media at relatively high concentrations that will allow further investigation and semi-synthetic optimization. The feeding of anthranilic acid enables the exclusive production of the stable elansolid derivative C1, which reduces product loss by unspecific reactions and eases downstream processing. This derivative shows activity in the same range as the elansolids A1/A2. Hence, the method can possibly serve as a model-process for incorporation of other nucleophiles and biotechnological production of specifically designed molecules.
Methicillin-resistant Staphylococcus aureus (MRSA) is at present the most commonly identified antibiotic-resistant pathogen in many parts of the world with a prevalence between 25 and 50% in most parts of America, Australia and southern Europe [1, 2]. In 2005, 19,000 deaths associated with MRSA strains were reported in the USA . Although infection rates are decreasing, MRSA infections were estimated to affect more than 150,000 patients in the EU alone in 2010 . Until recently, vancomycin and daptomycin have been the only effective treatment for methicillin-resistant pathogens . But in 1997, the first vancomycin-intermediate-resistant S. aureus strains were isolated, followed by reports of vancomycin-resistant ones in 2003 [6, 7]. Cases of daptomycin-resistant MRSA have also been described [8, 9]. Consequently, the need for new antibiotics for the treatment of these multi-resistant bacteria arises. In a global priority list released by the WHO in 2017, development of antibiotics against MRSA is given the second highest priority . To tackle this threat, efforts are undertaken to find new substances which can be developed as antibacterials. Our onset for discovery of novel molecules which show the desired biological activity is the investigation of culture-extracts from soil microorganisms which lead recently to the discovery of cystobactamids from myxobacteria . Moreover, the current medical need necessitates re-investigation of known substances like the chelocardins, where molecular engineering lead to novel chelocardin derivatives with a broadened gram-negative activity spectrum . Beside those gram-negative acting compounds other molecules like the disciformycins have been discovered in our laboratories, which show only a narrow-spectrum activity against gram-positive bacteria  but examples like the fourth generation cephalosporins have shown that the target spectrum can be expanded from solely gram-positive to a broad spectrum of gram-positive and gram-negative bacteria through medicinal chemistry approaches [14–16]. This underlines the importance of the investigation of any novel or under-investigated antibacterial activity since it harbor’s the possibility to address novel antibacterial targets or to overcome resistance problems associated with known antibacterial-targets.
To turn this highly interesting class of novel antibiotics into a lead for pharmaceutical development, it will be necessary to improve both their stability and potency. The compound class is amenable to various structural modifications by means of medicinal chemistry. However, for this purpose, the yields from biotechnological production need to be improved, in order to provide access to the starting material in multi gram scale.
Elansolid A3, which has hitherto been used as starting material for semi-synthesis approaches is highly unstable. Our rationale to direct the biotechnological production in order to allow for easy access of the starting material for a subsequent medicinal chemistry program is that it should be more feasible to produce elansolid A2. The latter compound can be converted back to elansolid A3 under mild conditions [17, 20]. For this reason, the biotechnological production of elansolid A2 with C. sancti was investigated in this study. One drawback of the biotechnological production has so far been the formation of several side products—especially in complex media—due to the reactivity of the elansolids A1–A3, which significantly lowered the yield of elansolid A2 in such a process. The reduced yield in undefined media arises from unspecific side reactions with either nucleophilic media components or intermediates, which are released by the producer itself due to cell lysis occuring in complex media when toxic metabolites accumulate. This might be circumvented by reducing formation of toxic metabolites and increasing the viability of the producer with the usage of a defined media and by concurrently directing the product formation towards a stable derivative through feeding of the corresponding precursor. The feasibility of this precursor-directed approach was explored in this study by feeding anthranilic acid, the precursor of elansolid C1 (6) which was shown to be incorporated in vivo and could thereby serve as a model system for direct incorporation of selected building blocks during the production process.
Media and supplements
For seed-cultures, medium (10.0 g L−1 soy peptone (Cargill), 1.0 g L−1 CaCl2·2 H2O, 1.0 g L−1 MgSO4·7 H2O, 8.0 mg L−1 Na–Fe-EDTA, 11.9 g L−1 HEPES; pH 7.4) was used to which maltose monohydrate was added after autoclaving to a final concentration of 10.5 g L−1. Bioreactor cultivations were conducted with a production medium (1.99 g L−1 (NH4)2SO4, 700 mg L−1 KH2PO4, 200 mg L−1 MgSO4·7 H2O, 8.0 mg L−1 Na–Fe-EDTA, 5.0 mg L−1 MnSO4·H2O, 1.0 mg L−1 ZnCl2; pH 7.0) to which the carbon sources were added after autoclaving giving the following final concentrations: 10.0 g L−1 sucrose; 10.1 g L−1 glucose monohydrate. To enable elansolid C1 production an anthranilic acid solution in methanol was prepared through sterile filtration and added to the bioreactor before inoculation to give a final concentration of 100 µg L−1. To capture the metabolites amberlite XAD16 resin (Sigma) was added to all production media to a concentration of 20 g L−1. Feed solutions contained 440 g L−1 glucose monohydrate and 146.7 g L−1 (NH4)2SO4 that were autoclaved separately and afterwards merged to add up to 500 mL.
Shake flask cultivations
250 mL shake flasks containing 100 mL pre-culture medium were inoculated with 1.8 mL cryo stock of Chitinophaga sancti Fx7914 and incubated at 25 °C and 160 rpm for 24 h. From this seed-culture, bioreactors were inoculated to a concentration of 10 g L−1.
All bioreactor cultivations were performed with the parallel cultivation system DASGIP (Eppendorf) and DASware control 5 for process control. The vessels had a total volume of 2.0 L. The system was equipped with optical DO electrodes (Hamilton) and pH electrodes (Hamilton). The off-gas analyzer consisted of zirconium dioxide sensors for O2 measurement and infrared sensors for CO2 measurement (BlueSens). The DO concentration in the medium was kept at a constant level of 20% by increasing the stirrer speed (200–1200 rpm) and adding pure oxygen to the gas mix if necessary, realized by an internal cascade. The gas flow rate was kept constant at 0.05 vvm. The pH level was kept constant as well by the addition of 50 g L−1 H2SO4 and 50 g L−1 KOH. When foaming occurred, Tegosipon anti foam (Evonik) was added with a 1 mL syringe. Batch fermentations were started with a cultivation volume of 1.5 L and lasted 85 h. The fed-batch fermentations were started with a cultivation volume of 1.0 L and lasted 94–190 h. The feed was started after 48 h for the sucrose glucose fermentation and after 24 h for the glucose fermentations with a feeding rate of F = 2.04·e0.056·t mL h−1.
Determination of optical density and substrate concentration
Optical density was determined with a Libra S11 photometer (Biochrom) at λ = 600 nm. Samples were diluted to be in the linear range of the photometer. Sucrose concentrations and corresponding monomeric glucose and fructose were determined with a photometric assay kit from r-biopharm (Art. No. 10716260035). For measuring of glucose concentration, a second method was applied using an Agilent 1260 series HPLC and a Phenomenex REZEX ROA-Organic Acid H+ (8%) column (300 mm × 7.8 mm × 8 µm) at 65 °C with a RID detector and an isocratic gradient of 0.05 mM H2SO4 for 45 min.
Adsorber resin extraction and determination of product concentration
After sample taking the amberlite XAD16 was filtered through gauze. The residual resin was weighed and the tenfold volume (w/v) of a 1% acetic acid solution in acetone (v/v) was added to the resin. After 10 min of incubation on a horizontal shaker 1 mL supernatant was centrifuged at 20,000g for 10 min. The supernatant was injected into an Agilent 1200 Series HPLC with a Waters Acquity UPLC BEH C18 column (50 mm × 2.1 mm × 1.7 µm) at 40 °C using 0.01% formic acid in water (v/v) and 0.01% formic acid in acetonitrile (v/v) as mobile phase. The gradient went linearly from 5 to 100% acetonitrile in 20 min. The UV signals were detected at λ = 220 nm. The product concentrations were determined via a calibration curve using five defined standard solutions.
Serial dilution assay for determination of antibacterial activity
Minimum inhibitory concentration (MIC) values were determined in standard microbroth dilution assays as described in . In brief, bacterial suspensions of Escherichia coli DSM-1116 and TolC-deficient E. coli were prepared in Müller-Hinton broth (104–105 cfu mL−1). In addition, the efflux-deficient E. coli strain was permeabilized with polymyxin B nonapeptide (PMBN) at a sub-inhibitory concentration (3 µg mL−1) and used for testing following the same procedure. Given MIC values are the lowest concentrations of antibiotic at which there was no visible growth.
Minimum inhibitory concentrations (MIC) in µg mL−1 of elansolids A2 and C1 against different E. coli strains
E. coli DSM1116
E. coli TolC
E. coli TolC + PMBN
According to Steinmetz et al.  it is crucial to use a defined medium without complex media components when producing elansolid A2 because otherwise elansolid C1, a derivative containing anthranilic acid, is produced instead of elansolid A2. A defined medium was developed for which sucrose was found to be the most suitable carbon source for elansolid A2 production during shake flask experiments with an elansolid A2 concentration of around 18 mg L−1 (data not shown).
Elansolids are interesting candidates for drug development, but chemical synthesis is to date only available for elansolid B1  and not feasible in multi-gram scale. Therefore, provision of substantial amounts of elansolids to enable further semi-synthetic drug development is only achievable by biotechnological means. The chosen strategy was two-fold: Our first approach aimed towards the production of elansolid A2. This is an ideal starting point for chemical optimization of the molecule where the ring-structure shall be retained whereas our second approach aimed towards the biotechnological production of a linearized derivative by adding a nucleophile (in our case anthranilic acid) to the culture, thereby preventing the accumulation of undesired side products.
In the batch fermentation, we could show that sucrose was cleaved and the monosaccharides were metabolized separately, with glucose as the preferred substrate, yielding 18.9 mg L−1 elansolid A2. The cleavage of sucrose might be carried out by extracellular invertases. These findings are well in accordance with publications showing that Chitinophaga pinensis, a close relative of C. sancti, possesses a variety of carbohydrate-active enzymes (CAZymes) for the degradation of carbohydrates, among them invertase [28–31]. The preferred usage of glucose over other carbon sources has been well observed in different types of organisms under the term carbon catabolite repression [32, 33].
To increase elansolid A2 production, a fed-batch fermentation was applied. Sucrose was chosen as the carbon source in the basal medium whereas glucose was provided in the feed solution as it was shown to enable rapid growth. Hence, the product concentration could be increased almost threefold from 18.8 mg L−1 in the batch fermentation to 55.3 mg L−1 in the fed-batch fermentation.
The fed-batch fermentation with glucose as sole carbon source resulted in only 31.8 mg L−1 elansolid A2 but 223.1 mg L−1 elansolid C1. Elansolid C1 is generated when anthranilic acid acts as a nucleophile that attacks the quinone methide ring of elansolid A3 . Since in this process anthranilic acid must be produced by the organism itself presumably as a precursor for tryptophan biosynthesis, accumulation of anthranilic acid and its subsequent side reactions with elansolid A3 could possibly be prevented by feeding tryptophan and thereby exploiting a possible feedback inhibition of the trp-operon . This will be subject of further research for process improvement. Furthermore, the feeding rates need to be adapted to avoid glucose accumulation during the feeding phase. In two of the fed-batch fermentations, glucose accumulated to final concentrations of 37.3 and 77.5 mg L−1 and although growth and product formation did not seem to be affected by a potential overflow metabolism, the accumulation of not metabolized substrates reduces process profitability and should therefore be minimized in future experiments.
To prove the concept of precursor-directed biosynthesis of novel elansolid derivatives that harbor several interesting advantages, anthranilic acid was provided in the medium as a precursor in another fermentation. Here, an elansolid C1 concentration of 257.5 mg L−1 has been obtained. This yield is equivalent to a 36-fold increase in product concentration compared to 7.1 mg L−1 which could be achieved by fermentation so far.
The precursor-directed biosynthesis during fermentation when providing anthranilic acid allowed the formation of the desired product in high amounts whereas formation of other elansolid derivatives occurred only in minor concentrations (85% elansolid C1, Fig. 6c). Accordingly, this procedure should be further investigated as basis for the creation of different novel elansolid derivatives, since the semi-synthetic approach within crude extracts proposed by Steinmetz et al.  is accompanied by a considerable loss of product.
The precursor-directed elansolid production is of special interest since although the absolute amount of elansolid A2 was increased considerably comparing absolute product titers of batch fermentation and fed-batch fermentation with sucrose, its share of the overall elansolid yield was similar with 14% in the batch (Fig. 3c) and 15% in the fed-batch process (Fig. 4c). The presence of these side-products increases the workload for purification of elansolid A2. Subsequently, after chromatographic purification of elansolid A2, which is additionally hampered by the stability of the molecule, the compound must be chemically converted into the desired product. This can only be accomplished with considerable losses at this time .
In this light, the precursor-directed synthesis of new elansolid derivatives directly during the fermentation might provide a promising tool in the search for novel antibiotics, especially since conversion into the more stable non-cyclic derivative elansolid C1 is accompanied by only a minor loss of activity even when observing gram-negative permeabilized cells. Thus, one focus of medicinal chemistry approaches could be the structure modification towards increased cell wall penetration. Another way to ensure antibiotic uptake is the formation of siderophore drug conjugates [35, 36]. Siderophores are high affinity Fe3+ chelators that are used for iron acquisition. The resulting Fe3+-siderophore complex is then assimilated through an active transport system by the bacteria. Hence, these siderophores could be coupled to antimicrobial compounds that enter the cell as a ‘Trojan horse’. Nonetheless, additional feeding experiments with different precursors will be conducted to fully prove the feasibility of this concept.
AB designed the study, carried out the fermentation experiments, evaluated the data and wrote the manuscript. SH designed the study and wrote the manuscript. VS carried out the serial dilution assays. MS and RM supervised the study and wrote the manuscript. All authors read and approved the final manuscript.
This project received funding from a Grant of the German BMBF within the programme InfectControl 2020 to R.M. and M.S. We are grateful to Dr. K. Mohr, Dr. Jennifer Hermann, Mr. Heinrich Steinmetz, Mr. Steffen Bernecker, Mrs. Silke Reinecke and all co-workers of the fermentation platform of the HZI for their contributions to previous results of the project and their help with technical aspects.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Consent for publication
Ethics approval and consent to participate
This project received funding from the BMBF in the programme “InfectControl 2020” (Grant for R.M. and M.S.).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006;368:874–85.View ArticleGoogle Scholar
- World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf. Accessed 2 May 2017.
- Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763–71.View ArticleGoogle Scholar
- Köck R, Becker K, Cookson B, van Gemert-Pijnen J, Harbarth S, Kluytmans J, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveil. 2010;15:19688.Google Scholar
- Kalimuddin S, Phillips R, Gandhi M, de Souza NN, Low JGH, Archuleta S, et al. Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial. Trials. 2014;15:233.View ArticleGoogle Scholar
- Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670–3.View ArticleGoogle Scholar
- Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003;348:1342–7.View ArticleGoogle Scholar
- Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285–7.View ArticleGoogle Scholar
- Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058–60.View ArticleGoogle Scholar
- World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1. Accessed 2 May 2017.
- Baumann S, Herrmann J, Raju R, Steinmetz H, Mohr KI, Hüttel S, et al. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antimicrobial activity. Angew Chem Int Ed. 2014;53:14605–9.View ArticleGoogle Scholar
- Lešnik U, Lukežič T, Podgoršek A, Horvat J, Polak T, Šala M, et al. Construction of a new class of tetracycline lead structures with potent antibacterial activity through biosynthetic engineering. Angew Chem Int Ed. 2015;54:3937–40.View ArticleGoogle Scholar
- Surup F, Viehrig K, Mohr KI, Herrmann J, Jansen R, Müller R. Disciformycins A and B: 12-membered macrolide glycoside antibiotics from the myxobacterium Pyxidicoccus fallax active against multiresistant staphylococci. Angew Chem Int Ed. 2014;53:13588–91.View ArticleGoogle Scholar
- Hancock REW, Bellido F. Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother. 1992;29:1–6.View ArticleGoogle Scholar
- Fung-Tomc JC. Fourth-generation cephalosporins. Clin Microbiol Newsl. 1997;19:129–36.View ArticleGoogle Scholar
- Karwehl S, Stadler M. Exploitation of fungal biodiversity for discovery of novel antibiotics. In: Stadler M, Dersch P, editors. How to overcome antibiotic crisis—facts, challenges, technologies and future perspectives. Cham: Springer International Publishing; 2016. p. 303–38.View ArticleGoogle Scholar
- Steinmetz H, Gerth K, Jansen R, Schläger N, Dehn R, Reinecke S, et al. Elansolid A, a unique macrolide antibiotic from Chitinophaga sancti isolated as two stable atropisomers. Angew Chem Int Ed. 2011;50:532–6.View ArticleGoogle Scholar
- Dehn R, Katsuyama Y, Weber A, Gerth K, Jansen R, Steinmetz H, et al. Molecular basis of elansolid biosynthesis: evidence for an unprecedented quinone methide initiated intramolecular Diels-Alder cycloaddition/macrolactonization. Angew Chem Int Ed. 2011;50:3882–7.View ArticleGoogle Scholar
- Mohr KI, Volz C, Jansen R, Wray V, Hoffmann J, Bernecker S, et al. Pinensins: the first antifungal lantibiotics. Angew Chem Int Ed. 2015;54:11254–8.View ArticleGoogle Scholar
- Jansen R, Gerth K, Steinmetz H, Reinecke S, Kessler W, Kirschning A, et al. Elansolid A3, a unique p-quinone methide antibiotic from Chitinophaga sancti. Chem Eur J. 2011;17:7739–44.View ArticleGoogle Scholar
- Steinmetz H, Zander W, Shushni MA, Jansen R, Gerth K, Dehn R, et al. Precursor-directed syntheses and biological evaluation of new elansolid derivatives. ChemBioChem. 2012;13:1813–7.View ArticleGoogle Scholar
- Wang LL, Candito D, Dräger G, Herrmann J, Müller R, Kirschning A. Harnessing a p-quinone methide intermediate in the biomimetic total synthesis of the highly active antibiotic 20-deoxy-elansolid B1. Chem Eur J. 2017;23:5291–8.View ArticleGoogle Scholar
- Pagès J-M, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in gram-negative bacteria. Nat Rev Microbiol. 2008;6:893–903.View ArticleGoogle Scholar
- Zeng AP. Effect of CO2 absorption on the measurement of CO2 evolution rate in aerobic and anaerobic continuous cultures. Appl Microbiol Biotechnol. 1995;42:688–91.View ArticleGoogle Scholar
- Aiba S, Furuse H. Some comments on respiratory quotient (RQ) determination from the analysis of exit gas from a fermentor. Biotechnol Bioeng. 1990;36:534–8.View ArticleGoogle Scholar
- Royce PN. Effect of changes in the pH and carbon dioxide evolution rate on the measured respiratory quotient of fermentations. Biotechnol Bioeng. 1992;40:1129–38.View ArticleGoogle Scholar
- Weber A, Dehn R, Schläger N, Dieter B, Kirschning A. Total synthesis of the antibiotic elansolid B1. Org Lett. 2014;16:568–71.View ArticleGoogle Scholar
- Kämpfer P, Young CC, Sridhar KR, Arun AB, Lai WA, Shen FT, et al. Transfer of [Flexibacter] sancti, [Flexibacter] filiformis, [Flexibacter] japonensis and [Cytophaga] arvensicola to the genus Chitinophaga and description of Chitinophaga skermanii sp. nov. Int J Syst Evol Microbiol. 2006;56:2223–8.View ArticleGoogle Scholar
- Glavina Del Rio T, Abt B, Spring S, Lapidus A, Nolan M, Tice H, et al. Complete genome sequence of Chitinophaga pinensis type strain (UQM 2034). Stand Genom Sci. 2010;2:87–95.View ArticleGoogle Scholar
- Lombard V, Golaconda Ramulu H, Drula E, Coutinho PM, Henrissat B. The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res. 2014;42:D490–5.View ArticleGoogle Scholar
- McKee LS, Brumer H. Growth of Chitinophaga pinensis on plant cell wall glycans and characterisation of a glycoside hydrolase family 27 β-L-arabinopyranosidase implicated in arabinogalactan utilisation. PLoS ONE. 2015;10:e0139932.View ArticleGoogle Scholar
- Deutscher J. The mechanisms of carbon catabolite repression in bacteria. Curr Opin Microbiol. 2008;11:87–93.View ArticleGoogle Scholar
- Görke B, Stülke J. Carbon catabolite repression in bacteria: many ways to make the most out of nutrients. Nat Rev Microbiol. 2008;6:613–24.View ArticleGoogle Scholar
- Yanofsky C, Platt T, Crawford IP, Nichols BP, Christie GE, Horowitz H, et al. The complete nucleotide sequence of the tryptophan operon of Escherichia coli. Nucleic Acids Res. 1981;9:6647–68.View ArticleGoogle Scholar
- Ji C, Juárez-Hernández RE, Miller MJ. Exploiting bacterial iron acquisition: siderophore conjugates. Future Med Chem. 2012;4:297–313.View ArticleGoogle Scholar
- Ferreira K, Hu HY, Fetz V, Prochnow H, Rais B, Müller PP, et al. Multivalent siderophore-DOTAM conjugates as theranostics for imaging and treatment of bacterial infections. Angew Chem Int Ed. 2017;56:8272–6.View ArticleGoogle Scholar